突变累积是一线奥希替尼治疗中出现的耐药机制
该研究采用ENU诱变筛选,在携带EGFR激活突变的Ba/F3细胞中比较吉非替尼、阿法替尼与奥希替尼的耐药突变谱。结果显示,在C797S/激活突变背景下,额外T790M是吉非替尼和阿法替尼筛选中的主要耐药机制,额外T854A和L792H仅在阿法替尼筛选中作为次要耐药机制出现,且可介导对各类EGFR-TKI的耐药;在单独激活突变背景下,吉非替尼联合奥希替尼筛选未出现由二次突变导致的耐药克隆。
要点
- C797S/激活突变背景下,额外T790M是吉非替尼和阿法替尼筛选的主要耐药机制。
- 额外T854A和L792H仅在阿法替尼筛选中出现,并可介导对各类EGFR-TKI耐药。
- 单独激活突变背景下,吉非替尼联合奥希替尼筛选未出现二次突变耐药克隆。
核心结论
- 在C797S/激活突变背景下,额外T854A和L792H是阿法替尼耐药而非吉非替尼耐药机制。
- 与阿法替尼相比,第一代EGFR-TKI可能更适合作为一线奥希替尼后出现C797S/激活突变患者的二线治疗。
研究设计与样本
- 采用N-乙基-N-亚硝基脲(ENU)诱变筛选,使用携带EGFR激活突变(伴或不伴二次耐药突变)的Ba/F3细胞。
- 细胞暴露于ENU 24小时后,分别用吉非替尼、阿法替尼或奥希替尼筛选,并评估耐药克隆的突变。
主要发现
- 在仅携带激活突变的Ba/F3细胞筛选中,T790M对吉非替尼耐药、C797S对奥希替尼耐药均普遍出现。
- 从表达C797S/激活突变的Ba/F3细胞中,额外T790M是吉非替尼和阿法替尼筛选的主要耐药机制。
- 额外T854A和L792H仅在阿法替尼筛选中作为次要耐药机制出现,并可介导对各类EGFR-TKI的耐药。
- 在仅携带激活突变的背景下,吉非替尼联合奥希替尼筛选未出现由二次突变导致的耐药克隆。
临床怎么用
- 对于一线奥希替尼治疗后出现C797S/激活突变的患者,二线治疗选择第一代EGFR-TKI可能优于阿法替尼。
- 需关注C797S/激活突变背景下额外T854A或L792H出现时对各类EGFR-TKI的交叉耐药。
局限性
- 研究基于Ba/F3细胞ENU诱变筛选模型,结果需临床样本验证。
- 未报告临床患者样本量、疗效数值或统计学比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The survival of patients with EGFR mutation-positive lung cancer has dramatically improved since the introduction of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Recently, osimertinib showed significantly prolonged progression-free survival than first-generation EGFR-TKI in first-line treatment, suggesting that a paradigm change that would move osimetinib to first-line treatment is indicated. We performed N-ethyl-N-nitrosourea (ENU) mutagenesis screening to uncover the resistant mechanism in first- and second-line osimertinib treatment. METHODS: Ba/F3 cells harboring EGFR activating-mutation with or without secondary resistant mutation were exposed to ENU for 24 hours to introduce random mutations and selected with gefitinib, afatinib, or osimertinib. Mutations of emerging resistant cells were assessed. RESULTS: The resistance of T790M and C797S to gefitinib and osimertinib, respectively, was prevalent in the mutagenesis screening with the Ba/F3 cells harboring activating-mutation alone. From C797S/activating-mutation expressing Ba/F3, the additional T790M was a major resistant mechanism in gefitinib and afatinib selection and the additional T854A and L792H were minor resistance mechanisms only in afatinib selection. However, the additional T854A or L792H mediated resistance to all classes of EGFR-TKI. Surprisingly, no resistant clone due to secondary mutation emerged from activating-mutation alone in the gefitinib + osimertinib selection. CONCLUSIONS: We showed the resistance mechanism to EGFR-TKI focusing on first- and second-line osimertinib using ENU mutagenesis screening. Additional T854A and L792H on C797S/activating-mutation were found as afatinib resistance and not as gefitinib resistance. Thus, compared to afatinib, the first-generation EGFR-TKI might be preferable as second-line treatment to C797S/activating-mutation emerging after first-line osimertinib treatment.
引用
- Uchibori K, Inase N, Nishio M, et al. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. J Thorac Oncol. 2018. PMID: 29702287. doi:10.1016/j.jtho.2018.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。